LENVIMA® for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer

Recommended dose and dose modifications1

Interrupt, reduce, and/or discontinue LENVIMA based on type and/or severity (grade) of AR

Recommended dose modifications for LENVIMA in RAI-refractory differentiated thyroid cancer Recommended dose modifications for LENVIMA in RAI-refractory differentiated thyroid cancer mobile

Capsules pictured are not actual size.

  • In SELECT, ARs led to dose reductions in 68% of patients receiving LENVIMA1
  • Treatment discontinuation due to ARs occurred in 18% of patients receiving LENVIMA1
  1. aReduce dose in succession based on the previous dose level (20 mg, 14 mg, or 10 mg per day).

For the management of specific adverse reactions, please see the AR management section below.


AR management

Help manage ARs with PI-guided strategies

Click on the bar of each AR for Pl-guided strategies. For the complete list of ARs, see full Prescribing Information.

  • Decreased appetite

    Decreased appetite-colored icon Decreased appetite-white icon

    PI-guided strategies to help manage decreased appetite1

    PI-guided-strategies to manage decreased appetite when taking LENVIMA for RAI-R differentiated thyroid cancer
  • Decreased weight

    Decreased weight-colored icon Decreased weight-white icon

    PI-guided strategies to help manage decreased weight1

    PI-guided-strategies to manage decreased weight when taking LENVIMA for RAI-R differentiated thyroid cancer

    CTCAE v4.0 does not define grade 4 decreased weight. Permanently discontinue for grade 4 adverse reactions.

  • Diarrhea

    Diarrhea-colored icon Diarrhea-white icon

    PI-guided strategies to help manage diarrhea1

    PI-guided strategies to manage diarrhea when taking LENVIMA for RAI-R differentiated thyroid cancer

    Promptly initiate management of diarrhea. Withhold and resume at a reduced dose upon recovery, or permanently discontinue LENVIMA based on severity.1

  • Hypertension

    Hypertension-colored icon Hypertension-white icon

    PI-guided strategies to help manage hypertension1

    Control BP prior to initiating treatment with LENVIMA

    PI-guided-strategies to manage hypertension when taking LENVIMA for RAI-R differentiated thyroid cancer
  • Fatigue

    Fatigue-colored icon Fatigue-white icon

    PI-guided strategies to help manage fatigue1

    PI-guided-strategies to manage fatigue when taking LENVIMA for RAI-R differentiated thyroid cancer

    CTCAE v4.0 does not define grade 4 fatigue. Permanently discontinue for grade 4 adverse reactions

  • Nausea

    Nausea-colored icon Nausea-white icon

    PI-guided strategies to help manage nausea1

    PI-guided-strategies to manage nausea when taking LENVIMA for RAI-R differentiated thyroid cancer

    CTCAE v4.0 does not define grade 4 nausea. Permanently discontinue for grade 4 adverse reactions.

  • Proteinuria

    Proteinuria-colored icon Proteinuria-white icon

    PI-guided strategies to help manage proteinuria1

    PI-guided strategies to manage proteinuria when taking LENVIMA for RAI-R differentiated thyroid cancer

AR=adverse reaction; PI=Prescribing Information; CTCAE=Common Terminology Criteria for Adverse Events; BP=blood pressure.

Download LENVIMA Access and Reimbursement Brochure icon

Download the LENVIMA AR Management Guide